ReSurfX, recently recognized as '20 Most Promising Data Analytics Vendors' by CIOReview is happy to announce accessibility of our SaaS product vysen (THE MOST ACCURATE IN THE MARKET) to more class of customers by pricing based on volume usage. Now we have expanded the access beyond the previous target of enterprise customers alone. Our value add is in line with many other accolades based on what we bring to the market and customers - including as an 'emerging company defining the next generation of personalized medicine platforms and technologies'.
ReSurfX has been recognized the "20 Most Promising Data Analytics Solutions Providers - 2017" by CIOReview magazine. We consider this a great honor that our creativity, value to market and customer centricity is recognized yet another time.
The list of 20 Companies can be seen here: http://data-analytics.cioreview.com/vendors/2017/
Another patent issued to ReSurfX in Israel. This is the 10th issued patent of ReSurfX, and expands the geographical scope of already very strong IP and patent portfolio of ReSurfX. The patent relates to parts of core technology invented by Suresh Gopalan, our CEO and Founder.
ReSurfX is proud to release our new version of our SaaS product ReSurfX::vysen 2.0 & a 30-day free trial version.
- This version features an awesome UI/UX tailored with modern features characteristic of smartphone generation not typically found in heavy duty analytics products. vysen 2.0 features great infrastructure built by experts with extreme security, scalability and customer enterprise integration perspective. The product is capable of repository scale processing and packs in the signature accuracy and innovation power, leveraging our novel 'Adaptive Hypersurface Technology' (AHT).
We are proud to welcome Dr. Fred Ausubel (Professor of Genetics, Harvard Medical School) an accomplished pioneer to our Board of Advisors effective February, 2015. We look forward to working with Dr. Ausubel to make faster progress towards our goals of enabling better data-based decisions and outcomes in life science and healthcare space, through improved accuracy and novel insights.
ReSurfX is proud to announce an agreement with a leading healthcare system to provide our solutions to a variety of problems. We believe this agreement will bring novel cost saving products and solutions for personalized and evidence based medicine to the healthcare marketplace with additional advantages and recognition to early adopters. We are also targeting to help research units make novel discoveries more effectively using our solutions.
Releasing our first web application product ReSurfX::vysen showcasing our novel 'Adaptive Hypersurface Technology' as a prelude to enterprise grade integrative analytics platform enabling better decisions and outcomes. This initial beta product is targeted towards data from a single gene expression technology.
ReSurfX assigned a new 'protein measurement' patent #8,483,994 by USPTO developed by Suresh Gopalan - issued on July 9, 2013. This is the eighth issued/allowed patent in 5 countries strengthening ReSurfX portfolio.
ReSurfX selected as an 'emerging company defining the next generation of personalized medicine platforms and technologies' at the Personalized Medicine World Conference (PMWC2013) in Silicon Valley January 28-29, 2013. We presented our novel platform for better data generation and utilization and our newest configuration that becomes an "Advance Outcomes Alert System' and their applications in drug development and patient care outcomes.
ReSurfX Inc. is proud to support the Big Data Summit: The Big Data Disruption by MassTLC on February 15, 2012. We are proud to continue to provide value to the ‘Big Data’ problems in unique ways through innovative measurement system designs and enterprise grade analytic solutions for increased ROI through reduced errors in data utilization. This Exhibitor/Showcase sponsorship shows our commitment to be a leading edge player in this vibrant ecosystem to solve major problems involving ‘Big Data’.